[Simultaneous determination of gallic acid and hesperidin contained in Xiaogu capsule by HPLC].

OBJECTIVE: To develop an HPLC method for simultaneous determination of gallic acid and hesperidin in Xiaogu capsule, in order to provide a simple, rapid and accurate method for quality control of the compound preparation of traditional Chinese medicine. METHOD: Xiaogu capsule was extracted with methanol heating reflux method. Synergi 4 mu Hydro-RP 80A (4.6 mm x 250 mm, 5 microm) was adopted as the chromatographic column, with acetonitrile--0.04 mol x L(-1) phosphate monobasic sodium solution (20: 80) as the mobile phase. The flow rate was 1.0 mL x min(-1), the detection wavelength was 283 nm, and the column temperature was 25 degrees C. RESULT: Under the conditions, gallic acid and hesperidin reached the baseline resolved peak, with a good linearity within the range of 21.6-216.0 mg x L(-1) (r = 0.999 93) for gallic acid, and 4.5-45.0 mg x L(-1) (r = 0.999 95) for hesperidin, respectively. Their average recoveries (n = 9) were 101.5% (RSD 3.7%) and 94.7% (RSD 2.7%), respectively. The average contents of gallic acid and hesperidin contained in Xiaogu capsule were detected to 5.10% and 0.091 1%, respectively. CONCLUSION: The method established in this study can determine the content of gallic acid and hesperidin contained in Xiaogu capsule in a rapid and accurate manner, which provided reference for quality evaluation of the medicine.

[Speciation of arsenic(III) and arsenic(V) in water by hydride generation atomic fluorescence spectrometry].

A method for arsenic(III) and arsenic(V) speciation in water samples using HG-AFS was established. Without any preseparation technique, the speciation was simply accomplished by just adjustment of the acidity for hydride generation. For a sensitive, reproducible and accurate determination, other conditions for hydride generation, such as the concentration of NaBH4 and the added amount of KI as the reductant for arsenic(V), were also optimized, and the interference experiment was carried out for concomitant elements. As a result, a detection limit of 0.026 microg x L(-1), a relative standard deviation of 2%, and a recovery of 97. 5%-103. 0% were obtained, indicating the robustness of the method.

[Determination of Pb and Al in blood and hair of child using transverse heated graphite furnace atomic absorption spectroscopy].

Pb and Al in blood and hair of child were determined by transverse heated graphite furnace atomic absorption spectrometry with NH4H2PO4 and Mg(NO3)2 as a modifier, which enhanced the temperature of ashing, eliminated the matrix interference and memorial effect. The method is rapid, simple and accurate. The characteristic mass of the method was 2.3 x 10(-11) g and 2.2 x 10(-11) g for Pb and Al respectively. The relative standard deviation of Pb and Al was 3.0% and 11.4%, respectively, and the recovery was 96%-102%.

[Study of solid-phase time-resolved fluorescence label immunoassay].

This paper describes optimal conditions for HBsAbIgG labeling with a new fluorescence probe, 4,7-bis-chorosulfophenyl-1,10-phenanthroline-2,9-dicarboxylic acid (BCPDA) for the solid phase time-resolved fluorimmunoassay (TRFIA). The result of experiment under states clearly that BCPDA may react with protein under relative mild condition. The relative bioactivity of reacted protein was more than 80%. The labeling molar ratio of BCPDA for HBsAbIgG was 45-70. The recovery was higher than 80%. Protein-BCPDA-Eu3+ complex is stable. It can emit very high fluorescence intensity with very long fluorescence life times. The fluorescence of Protein-BCPDA-Eu3+ complex has a very large stokes shift (270 nm). The emission band at 611.2 nm is very narrow. The research provides the base for developing non-isotopic immunoassay technique and clinical medical diagnosis.

[Study of rare earth bifunctional chelate BCPDA-Eu3+ labeling protein].

The authors labeled bovine serum albumin (BSA) with a new europium chelator 4,7-bis(chlorosulfophenyl)-1,10-phenanthroline-2,9-dicarboxylic acid (BCPDA) which was synthesized by solid phase time-resolved fluorescence immunoassay (TRFIA) technology. The process of BCPDA-labeling-BSA reaction was studied. Using Coomassie brilliant blue method, concentrations of BSA and BCPDA were determined in BCPDA-BSA labeled sample. The labeling reaction condition was studied. Labeling ratio and protein labeling recovery were calculated. BCPDA-BSA-Eu3+ complex has a very large Stokes shift (270 nm) and can emit very strong fluorescence band at 611.2 nm which is very narrow (10 nm). BCPDA-BSA-Eu3+ complex exhibits very long fluorescence lifetimes by the experiment demonstration. Also, BCPDA and protein-BCPDA-Eu3+ complex is relatively stable.